Neurocrine Biosciences Presents New Clinically Meaningful Response Data on Treatment of Tardive Dyskinesia, Reinforcing the Efficacy of INGREZZA® (valbenazine) Capsules Across a Broad Range of Patients
Neurocrine Biosciences presented new post-hoc data from the KINECT 4 Phase 3 trial, showing that 94% of patients treated with INGREZZA for 48 weeks achieved either symptomatic remission or a clinically meaningful response (≥30% reduction in AIMS score). Among the 41% of patients who did not meet the stringent remission threshold, 86% still achieved a ≥30% reduction in movement severity, reinforcing the drug's efficacy across a broad patient population.
Key figures
- Drug Name
- INGREZZA (valbenazine)
- Remission rate
- 59%
- Medicare patients analyzed
- 176000
- Patients with hepatic risk
- 90%
- Response rate non remitters
- 86%
- High response rate non remitters
- 67%
- Patients with 3 plus risk factors
- 44%
- Clinically meaningful response rate
- 94%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.